Cargando…

5613426 LOW CHRONIC INFLAMMATION IN SCD

Detalles Bibliográficos
Autores principales:	Rolli, M.R., Venturelli, D.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	e-Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112564/ http://dx.doi.org/10.1097/01.HS9.0000928432.67312.cf

Ejemplares similares

5613386 CELEBRATING THE SICKLE CELL DISEASE WORLD DAY ON JUNE 19TH AFTER TWO YEARS OF PANDEMIC: MY LIFE WITH SCD, PATIENTS’ PERSPECTIVE
por: Maran, J.E.M., et al.
Publicado: (2023)

Adult T-cell leukemia/lymphoma following elevation of serum levels of soluble cytokine receptors, sCD25 and sCD30
por: Takemoto, Shigeki, et al.
Publicado: (2014)

P-004: HEALTH CARE TRANSITION (HCT) FOR SICKLE CELL DISEASE (SCD) CAN BE STANDARDIZED: RESULTS OF IMPLEMENTING A SCD HCT LEARNING COLLABORATIVE.
por: I., OSUNKWO, et al.
Publicado: (2022)

P1480: SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/Β0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY
por: Allard, P., et al.
Publicado: (2022)

P110: CLINICAL CHARACTERISTICS OF COVID-19 IN SICKLE CELL DISEASE (SCD) PATIENTS
por: Malhan, H, et al.
Publicado: (2022)

P103: THE ABNORMAL PRESENCE OF MITOCHONDRIA IN CIRCULATING SCD RED BLOOD CELLS ASSOCIATED WITH STRESS ERYTHROPOIESIS
por: Ramasamy, J, et al.
Publicado: (2022)

Soluble haemoglobin scavenger receptor (sCD163): a marker associated with bacteraemia
por: Gaïni, S, et al.
Publicado: (2005)

The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models
por: Shirakawa, K, et al.
Publicado: (2010)

Procalcitonin, IL-10 and sCD25 as diagnostic and prognostic markers in critically ill patients
por: Focà, A, et al.
Publicado: (2012)

5613480 REAL WORLD APPLICATIONS OF CLINICAL WHOLE BLOOD ADHESION (VCAM AND P-SELECTIN) BIOMARKERS IN A PEDIATRIC SCD POPULATION
por: Martin, O.Y., et al.
Publicado: (2023)

Presepsin (sCD14-ST) as a new diagnostic biomarker of sepsis: development of diagnostic tools using the whole blood
por: Shozushima, T
Publicado: (2011)

Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis in systemic inflammatory response syndrome
por: Shozushima, T, et al.
Publicado: (2011)

Effect of restoration of 25OHD(3 )status in prolonged critical illness on serum innate immunity parameters LL-37 and sCD163
por: Ingels, CM, et al.
Publicado: (2010)

P-030: CRIZANLIZUMAB REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SCD PATIENTS IN STANDARDIZED MICROFLUIDIC PLATFORM: IN VITRO TECHNOLOGY ASSESSMENT
por: C., FEDERICI, et al.
Publicado: (2022)

Lymphoid neogenesis in chronic inflammation
por: Pitzalis, C, et al.
Publicado: (2003)

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: B., ANDEMARIAM, et al.
Publicado: (2022)

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
por: C., SEGBEFIA, et al.
Publicado: (2022)

Compared values of presepsin (sCD14-ST) and procalcitonin as early markers of outcome in severe sepsis and septic shock: a preliminary report from the Albumin Italian Outcome Sepsis (ALBIOS) study
por: Caironi, P, et al.
Publicado: (2013)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

PD53 - Budesonide therapy reduces sCD30-levels in atopic infants with recurrent respiratory symptoms
por: Kotaniemi-Syrjänen, Anne, et al.
Publicado: (2014)

Citrullinated α enolase, a novel citrullinated autoantigen in rheumatoid arthritis, upregulated by chronic inflammation
por: Kinloch, A, et al.
Publicado: (2005)

Comparison of global extracellular volume (ECV) and late gadolinium enhancement (LGE) to predict the estimated 5 year risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM)
por: Avanesov, Maxim, et al.
Publicado: (2016)

5610823 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Bartolucci, P., et al.
Publicado: (2023)

P119: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Bartolucci, P, et al.
Publicado: (2022)

Surface functionalized nanoparticles of NVP an improved strategy to tackle deadly HIV infection
por: Dalvi, Bhagyashree R, et al.
Publicado: (2014)

5597199 AGEING WITH SICKLE CELL ANEMIA AND HOW TO FACE IT
por: Kreka, M.K., et al.
Publicado: (2023)

5574716 PROBLEMS AND STRATEGIES OF BLOOD TRANSFUSION IN THALASSEMIA DURING COVID-19 PANDEMIC IN INDONESIA
por: Rahmartani, L.D.R., et al.
Publicado: (2023)

5558131 GENETICS OF IRANIAN ALPHA THALASSEMIA PATIENTS; COMPREHENSIVE ORIGINAL STUDY
por: Khosravi, A., et al.
Publicado: (2023)

5588005 IMPACT OF COVID-19 PANDEMIC TO PRE-TRANSFUSION HEMOGLOBIN LEVEL AND FREQUENCY OF TRANSFUSION IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS IN INDONESIA
por: Dewi, M.K.D., et al.
Publicado: (2023)

Assessment of the anti-HBV like property of BEHP – a phthalate derivative and its insilico characterization
por: Girija, AS Smiline, et al.
Publicado: (2014)

Regulation of macrophage-mediated chronic inflammation by JAK inhibitors
por: Yarilina, Anna, et al.
Publicado: (2012)

5612539 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Callaghan, M., et al.
Publicado: (2023)

Arterial stiffness as a model to dissect chronic inflammation in FMF
por: Kukuy, O, et al.
Publicado: (2015)

P120: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Callaghan, M, et al.
Publicado: (2022)

Development of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection
por: Chikhale, Rupesh V, et al.
Publicado: (2014)

5612560 A MONITORING AND EVALUATION FRAMEWORK AND ASSOCIATED TOOLS FOR THE SICKLEINAFRICA CONSORTIUM
por: Nembaware, V., et al.
Publicado: (2023)

P1628: ALLOIMMUNIZATION DURING ASSISTED REPRODUCTIVE TECNOLOGY: CASE REPORT OF A PREGNANCY WITH IRREGULAR ANTIBODIES PROBABILY RELATED TO EGG DONOR ANTIGEN.
por: Rolli, M., et al.
Publicado: (2022)

5612535 THE IMPACT OF COVID19 PANDEMIC ON TRANSFUSION DEPENDENT -THALASSEMIA MANAGEMENT: EXPERIENCE OF A SINGLE PEDIATRIC TREATMENT CENTER
por: Maria Vousvouki, M.V., et al.
Publicado: (2023)

5610131 A STANDARDISED LANGUAGE TAG PROTOCOL AND WORKFLOW FOR DEVELOPING AND MANAGING MULTILINGUAL ONTOLOGIES: SHOWCASING THE FRENCH SICKLE CELL DISEASE ONTOLOGY (SCDO)
por: Hotchkiss, J., et al.
Publicado: (2023)

Metabolic changes in human bronchial epithelial cells upon chronic exposure to hexavalent chromium
por: Ferreira, Leonardo MR, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_261oi0k9q3daehg8s9k5npqhsa